IFNB1 and neoplasm: Here, we investigated whether greater reduction of the tumor burden could be achieved by using targeted delivery of canine AT-MSCs (cAT-MSC) expressing IFN-β in combination with a low dose cisplatin (cis-diamminedichloroplatinum) protocol.